Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025)

Artiva Biotherapeutics' (ARTV) quarterly Capital Leases came in at $11000.0 in Q1 2025, down 75.0% on a QoQ basis from $44000.0 in Q4 2024.

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Capital Leases data on file, last reported at $11000.0 in Q1 2025.

On a quarterly basis, Capital Leases changed N/A year-over-year to $11000.0 in Q1 2025; TTM through Mar 2025 was $11000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $44000.0, changed N/A from the prior year.
Capital Leases for Q1 2025 stood at $11000.0, down from $44000.0 in the prior quarter.
Over the last five years, Capital Leases for ARTV reached as high as $106000.0 in Q2 2024 and fell as low as $11000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Artiva Biotherapeutics	256.04 Mn	256.04 Mn	-

Download Data